EHA 2023 | Results of Phase I study of MCL-1 inhibition with AZD5991 in R/R hematologic malignancies
Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York City, NY, comments on the results of a Phase I study of the MCL-1 inhibitor AZD5991 in patients with relapsed/refractory (R/R) hematologic malignancies. The study demonstrated some responses in patients with myelodysplastic syndromes (MDS), but also reported a dose-dependent toxicity increase manifested as asymptomatic troponin elevation. Consequently, these outcomes prompted the termination of the study, emphasizing the need for additional research to comprehend the cardiotoxicity associated with these agents and establish preventive measures. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Servier, Janssen Research
